On April 6, 2026, Freedom Broker initiated coverage of AngioDynamics (NasdaqGS: ANGO) with a “Buy” recommendation, projecting a 103.30% upside. The average one-year price target for the stock is $19.72 per share, based on forecasts ranging from $16.16 to $25.20, compared to its latest closing price of $9.70 per share.
The projected annual revenue for AngioDynamics is $420 million, reflecting a 33.82% increase, while the forecasted non-GAAP EPS is expected to be $1.07, representing a 48.44% rise. However, institutional ownership has dropped by 45.66% in the last quarter, with total shares owned decreasing by 13% to 38,796K shares, and a put/call ratio of 1.83 indicates a bearish outlook.
